Get the Stockscreener App
17.94
8.93%
-1.76
After Hours:
17.94
Spyre Therapeutics Inc Stock (SYRE) Latest News
Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World
Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN
Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat
Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks
Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com
Spyre Therapeutics: Q4 Earnings Snapshot - The Washington Post
Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks
Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks
Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat
Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World
Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily
SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com
IBD-Focused Spyre Therapeutics Sets Investor Conference Schedule for MarchWhat to Expect - StockTitan
Spyre Therapeutics (NASDAQ:SYRE) Shares Down 6.7%Time to Sell? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World
Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN
InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com
Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan
China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - cnhinews.com
A company insider recently sold 6,700 shares of Spyre Therapeutics Inc [SYRE]. Should You also Consider to Sale? - Knox Daily
Financial Analysis: Spyre Therapeutics Inc (SYRE)’s Ratios Unveil Key Insights - The Dwinnex
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc.SYRE - PR Newswire
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Oruka Therapeutics initiated with an Outperform at Wolfe Research - MSN
Spyre Therapeutics Announces Grants of Inducement Awards - PR Newswire
JPMorgan Chase & Co. Has $867,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Has $527,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Assenagon Asset Management S.A. Cuts Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat
Analysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) Target Price at $54.83 - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 9.4%Time to Buy? - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3%What's Next? - MarketBeat
Lifesci Capital Has Positive Outlook of SYRE FY2024 Earnings - Defense World
FY2024 EPS Forecast for Spyre Therapeutics Lifted by Analyst - MarketBeat
Get Caught Trying - Audacy
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at Wedbush - MarketBeat
Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PR Newswire
Spyre Therapeutics Unveils Ambitious 2025 Pipeline Plans with $600M Cash Runway Through 2028 - StockTitan
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2%Here's Why - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):